Boehringer, WellPoint studying outcomes in AF

Boehringer Ingelheim GmbH (Ingelheim, Germany) and the HealthCore Inc. unit of WellPoint Inc. (NYSE:WLP) have identified non-valvular atrial fibrillation (NVAF) as the first project under their July deal to collaborate on the collection of real world health economic and outcomes data.

HealthCore, which is Wellpoint's outcomes research arm, and BI said they chose to study non-valvular AF because new anticoagulant therapies have begun to replace warfarin.The partners plan to study disease prevalence, treatment complications such as hospital readmissions and the use of evidence-based guidelines. ...